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Abstract
Post-exposure prophylaxis (PEP) for leprosy is administered as one single dose of rifampicin (SDR) to the contacts of
newly diagnosed leprosy patients. SDR reduces the risk of developing leprosy among contacts by around 60 % in
the first 2–3 years after receiving SDR. In countries where SDR is currently being implemented under routine
programme conditions in defined areas, questions were raised by health authorities and professional bodies about
the possible risk of inducing rifampicin resistance among the M. tuberculosis strains circulating in these areas. This
issue has not been addressed in scientific literature to date. To produce an authoritative consensus statement about
the risk that SDR would induce rifampicin-resistant tuberculosis, a meeting was convened with tuberculosis (TB) and
leprosy experts. The experts carefully reviewed and discussed the available evidence regarding the mechanisms and
risk factors for the development of (multi) drug-resistance in M. tuberculosis with a view to the special situation of
the use of SDR as PEP for leprosy. They concluded that SDR given to contacts of leprosy patients, in the absence of
symptoms of active TB, poses a negligible risk of generating resistance in M. tuberculosis in individuals and at the
population level. Thus, the benefits of SDR prophylaxis in reducing the risk of developing leprosy in contacts of
new leprosy patients far outweigh the risks of generating drug resistance in M. tuberculosis.
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Introduction
In post-exposure prophylaxis (PEP) for leprosy, one sin-
gle dose of rifampicin (SDR) (600 mg for adults and ap-
propriately reduced doses for children) is administered
to the contacts of newly diagnosed leprosy patients to
reduce their risk of developing leprosy. These contacts
comprise household members, neighbours and defined
social contacts, and may include around 20 persons
(with a range of 5 – 50) per leprosy patient. Robust evi-
dence for the effectiveness of SDR as PEP for leprosy
has been generated through two large field-level trials.
The first was a non-randomised controlled trial in
Indonesia [1] and the second a randomised double-blind
placebo-controlled field trial in Bangladesh [2]. In both
studies, SDR administered to contacts of leprosy patients
provided close to 60 % protection against developing
leprosy among contacts within the first 2–3 years after
receiving SDR. Interestingly, the size of the effect was
comparable to that of more prolonged dapsone prophy-
laxis, which was tested in the 1960s and 70s [3]. The
effect was sustained for up to 10 years of follow-up.
Sub-group analysis suggested that when SDR was given
to subjects who had had Bacillus Calmette-Guérin
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(BCG) immunization in infancy, the protective effect
reached 80 %. A new clinical trial designed to specific-
ally test the protective effect of SDR plus a further dose
of BCG in contacts, is currently under way [4].
The leprosy post-exposure prophylaxis (LPEP) project
is now being implemented in selected areas of India,
Indonesia, Myanmar, Nepal, Sri Lanka and Tanzania by
the respective Ministries of Health in partnership with
members of the International Federation of Anti-Leprosy
Associations (ILEP) and scientific partners, under coord-
ination and with support from the Novartis Foundation.
The project aims to assess the feasibility of implementing
SDR as PEP for leprosy under routine programme condi-
tions and evaluate the impact of the intervention on lep-
rosy incidence over time.
During the preparatory work for the LPEP project, ques-
tions and doubts were raised by health authorities and
professional bodies about the possible risk of inducing ri-
fampicin resistance among the Mycobacterium tubercu-
losis (M. tuberculosis) strains circulating in the areas were
the LPEP project is implemented. The scientific literature
has not specifically addressed this issue to date.
For this reason, an expert meeting was convened to
assess the risk of drug resistance in M. tuberculosis by
administering SDR to contacts of leprosy patients. This
high level consultation involved experts in both leprosy
and TB from a range of disciplines and had as its objective
to produce an authoritative consensus statement about
the risk that SDR would induce rifampicin-resistant TB.
Review
Mechanisms related to drug resistance in mycobacterium
tuberculosis
The World Health Organization (WHO) estimates
that there are 9 million TB patients globally with an
annual mortality of 1.1 million cases (excluding cases
with a combined TB/HIV infection). The number of
patients with multidrug-resistant TB (MDR-TB) is es-
timated at 480 000, among whom 210 000 deaths
occur every year [5].
The vast majority of TB patients can be cured with a
standard 6-month treatment course of four antimicrobial
drugs comprising of isoniazid, rifampicin, ethambutol
and pyrazinamide in the first 2-month intensive phase,
followed by isoniazid and rifampicin in the subsequent
4-month continuation phase. Correct dosing and regular
drug intake are essential to ensure treatment success
and reduce the risk of drug resistance. MDR-TB is
caused by M. tuberculosis resistant to, at least, isoniazid
and rifampicin, the two most powerful first-line anti-TB
drugs. The primary cause of MDR-TB is irregular treat-
ment but inappropriate or incorrect use of anti-TB drugs
and use of poor quality medicines also contribute to
drug resistance formation.
Drug resistance in M. tuberculosis is the result of the
sequential accumulation of mutations in genetically iso-
lated mycobacterial lineages [6]. As DNA replication is
not perfect, any sufficiently large population of bacteria
will randomly contain a small number of mutants with
single nucleotide polymorphisms (SNPs) that may result
in resistance to an antibiotic. Prolonged treatment of pa-
tients with a large enough population of bacteria (usually
more than 108 organisms) with a single anti-TB drug
(e.g. rifampicin) will select the bacteria containing these
SNPs [7]. Sustained antibiotic pressure provides an ad-
vantage for resistant mutants, as growth of the sensitive
form is suppressed, and allows adaptation and genetic
fixing of the resistant genotype [8, 9]. Sufficiently large
bacterial populations for this genetic fixing to take place
are found in patients with pulmonary TB, especially
when cavities are present. In solid pulmonary lesions,
extra pulmonary TB or in latent TB infections without
pulmonary involvement, the number of organisms is
small enough to make the generation of drug-resistant
TB unlikely.
Probability of the development of drug resistance in
Mycobacterium tuberculosis
The probability of the emergence of MDR-TB depends
on the potency and the number of different drugs used
for treatment, and on the mycobacterial load [10]. With
a potent and correctly administered multidrug regimen,
the probability of drug resistance developing appears to
be very low, even in the presence of high bacterial loads
as found in pulmonary cavitary disease. However, a
recent modeling study suggested that the probability of
resistance development is several orders of magnitude
higher than previous estimates [11]. Furthermore, there
appears to be a possibility of mutagenesis from M. tuber-
culosis persisters (or stressed cells) transiently exposed
to low concentrations of antimicrobial drugs [12]. Inter-
mittent therapy with drugs thus portends a higher risk
of developing resistance in M. tuberculosis than daily
treatment, especially in HIV-infected subjects [13]. This
is likely due to the regrowth of bacilli with different sus-
ceptibilities in the interval between two periods of
chemotherapy [14].
In the original 14-day Early Bactericidal Activity (EBA)
study, using either isoniazid, rifampicin or ofloxacin, it
was found that drug resistance occurred in only 1 of 12
patients [15]. In early trials of isoniazid (INH) monother-
apy in India, where half of the patients took INH alone
for 12 months, it was shown that it took up to 12 months
for INH resistance to appear [16]. Numerous subsequent
EBA studies used isoniazid as a positive control and
drug resistance was never encountered in tests done
after less than 2 weeks of monotherapy [17]. This sug-
gests that resistance development after a few doses of
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monotherapy is very rare, and thus highly unlikely to
emerge after the administration of a single dose.
Acquired resistance to rifampicin in M. tuberculosis has
also not been reported to be a frequent problem with
rifamycin-based regimens for the treatment of latent TB
infection (as only 2 out of 3 such trials had a few patients
developing rifamycin-resistant TB), with the caveat that
the currently available database is relatively small [18].
Risk factors for inducing drug resistance in M. tuberculosis
through SDR administration
Any use of antibiotics bears at least a minimal risk of re-
sistance development [19]. Two risk factors are particu-
larly important for the development of drug resistance
in M. tuberculosis: (i) the prolonged and/or repeated ex-
posure to a single antibiotic; and (ii) its administration
to a person with a substantial load of M. tuberculosis ba-
cilli. Neither risk factor is present in the context of SDR
administration to contacts of leprosy patients. The in-
take of SDR is supervised and contacts are screened for
classical symptoms of TB: cough (>2 weeks), night sweats,
unexplained fever or weight loss.
Excluding contacts with any of the classical TB symp-
toms will reduce the risk of SDR being given to people
with clinical TB and thus individuals harbouring a sig-
nificant number of bacilli. Administration of SDR to an
individual with sub-clinical TB disease or a latent TB in-
fection bears negligible risk of that individual developing
rifampicin-resistant TB as the number of M. tuberculosis
bacilli make it highly unlikely that the relevant mutation
were present at the time of SDR administration, and no
selective pressure would continue to exist to favour the
growth of resistant bacilli. To further minimize the risk,
the LPEP protocol excludes from SDR administration all
contacts who have taken rifampicin for any reason in the
past two years.
Excluding active TB by screening algorithm
Provider initiated screening for TB, which is done before
SDR is given, is best done by symptom screening. Any
presumed TB patient is referred to the National TB
Programme for further diagnosis.
TB prevalence surveys suggest that 15-38 % of all infec-
tious TB patients show no symptoms, and that 50-75 % of
all infectious cases do not fulfil the classic criteria to sus-
pect TB listed above [20, 21]. An evaluation of the screen-
ing algorithm for TB showed that the sensitivity of the
screening increased substantially when ‘coughing for any
duration’ was used for symptom screening, instead of
‘coughing for > 2 weeks’ (from 46.8 % to 59.5 %). Also, TB
symptom screening is less sensitive when used for
provider-initiated TB screening (i.e. active case finding),
and the sensitivity is also negatively affected by the HIV
status [22].
The positive and negative predictive value (NPV: the
likelihood that a person who tested negative in TB
screening does not have culture-positive TB) of a TB
screening test is dependent on the prevalence of TB dis-
ease in the community screened [23]. In summary, no
screening strategy achieves perfect sensitivity and speci-
ficity as all strategies will miss some TB patients or de-
clare an unacceptably high proportion of uninfected
individuals as TB suspects. Nevertheless, it is universally
accepted that TB symptom screening provides a quick,
cheap and convenient way to identify individuals with a
high risk of TB disease, who then need to undergo
further investigation with more definitive tests such as
chest radiography, sputum microscopy, Xpert MTB/Rif
and culture.
The WHO, with partners, has developed a guideline
on screening for active TB [24], based on four systematic
reviews and a series of expert consultations [25]. The
options for initial screening of adults and children aged
10 years and older include TB symptom screening or
screening with chest radiography, which is more sensi-
tive but also more expensive.
Discussion
The main benefit of the SDR prophylaxis for contacts of
leprosy patients is that it reduces their risk of developing
leprosy by about 60 %. By giving SDR only to those con-
tacts that do not have any of the classical TB symptoms
the likelihood of giving it to a person with TB, especially
one with pulmonary cavitary disease, is minimised. Fur-
thermore, a single dose, as opposed to a repeated or a pro-
longed course of monotherapy, is not expected to have
the power to cause selection of resistant mutants even if
inadvertently given to contacts with a high bacterial load.
None the less, repeated use of rifampicin prophylaxis in
an individual, who for example may be a contact of mul-
tiple leprosy patients, should be minimised. Repeated use
of rifampicin prophylaxis would be expected to increase
the risk of selecting resistance slightly but the degree of
this risk has not been determined. The quality of the drug
should be assured, the logistics of its distribution should
be controlled, and the intake of the single dose should be
supervised. In areas with a known high prevalence of
primary MDR-TB caution is needed because exposure
to rifampicin in such areas may provide an advantage
for already drug-resistant M. tuberculosis [26].
The 60 % reduction in the risk that contacts of leprosy
patients will develop leprosy is an important benefit
that, according to the opinion of the experts convened
in this meeting, far outweighs the theoretical and ex-
tremely small chance of selecting rifampicin-resistant
M. tuberculosis.
Rifampicin prophylaxis also assumes and relies on ri-
fampicin sensitivity of the circulating Mycobacterium
Mieras et al. Infectious Diseases of Poverty  (2016) 5:46 Page 3 of 5
leprae (M. leprae) strains [27]. Regular sampling and
molecular monitoring for mutations associated with ri-
fampicin resistance in M. tuberculosis as well as in M.
leprae should be considered in areas where SDR is given
to contacts of leprosy patients. Such intensified monitor-
ing of rifampicin resistance in M. tuberculosis and M.
leprae is particularly important in areas with a high rate
of primary MDR-TB, and among the recipients of SDR
who develop leprosy.
Conclusion
Based on the proven efficacy in randomized controlled
trials, SDR is given to contacts of leprosy patients as
PEP. The multi-disciplinary experts in leprosy and TB
attending this meeting carefully reviewed and discussed
the available evidence regarding the mechanisms and
risk factors for the development of (multi) drug-
resistance in M. tuberculosis with a view to the special
situation of the use of SDR as PEP for leprosy. They
concluded that SDR given to contacts of leprosy pa-
tients, in the absence of symptoms of active TB, poses a
negligible risk of generating resistance in M. tuberculosis
in individuals and at the population level. Thus, the bene-
fits of SDR prophylaxis in reducing the risk of developing
leprosy in contacts of new leprosy patients far outweigh
the risks of generating drug resistance in M. tuberculosis.
Ethical approval
No ethical approval was required to conduct this meeting.
Participants in the meeting, other than the (co-)
authors:
 Dr Indira Padmapani Kahawita, Consultant
Dermatologist, Ministry of Health, Colombo,
Sri Lanka
 Mr René Stäheli, Director, FAIRMED, Bern, Switzerland
Observer:
 Dr Linh Nguyen, WHO, Global TB Programme,
Geneva, Switzerland
Additional file
Additional file 1: Multilingual abstracts in the six official working
languages of the United Nations. (PDF 303 kb)
Abbreviations
BCG: bacillus calmette-guérin; DNA: deoxyribonucleic acid; EBA: early
bactericidal activity; HIV: human immunodeficiency virus; ILEP: international
federation of anti-leprosy associations; INH: isoniazid; LPEP: leprosy post-exposure
prophylaxis; M: mycobacterium; MDR: multidrug-resistant; NPV: negative
predictive value; PEP: post-exposure prophylaxis; SDR: single dose rifampicin;
SNPs: single nucleotide polymorphisms; TB: tuberculosis; WHO: World Health
Organization.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
All authors contributed to the manuscript by actively being involved in the
expert meeting to assess the risk of drug resistance in M. tuberculosis by
administering SDR to contacts of leprosy patients and by helping to draft
the manuscript. All authors helped revising the manuscript, read and
approved the final version.
Acknowledgements
The expert meeting on the risk of TB drug resistance due to SDR given as
PEP to contacts of leprosy patients was held on May 26th 2015 in Utrecht,
the Netherlands. The meeting was supported by Novartis Foundation as
coordinator of the LPEP project and hosted by the Netherlands Leprosy
Relief, one of the ILEP partners involved in the LPEP project.
Author details
1Netherlands Leprosy Relief, P.O. Box 95005, 1090 HA Amsterdam, The
Netherlands. 2Royal Tropical Institute (KIT), Amsterdam, The Netherlands.
3Swiss Tropical and Public Health Institute, Basel, Switzerland. 4Independent
TB and Leprosy Consultant, Helmond, The Netherlands. 5French National
Reference Center for Mycobacteria, Paris, France. 6Novartis Foundation, Basel,
Switzerland. 7The German Leprosy and Tuberculosis Relief Association,
Würzburg, Germany. 8Ministry of Health, Colombo, Sri Lanka. 9New Jersey
Medical School Global Tuberculosis Institute, New Jersey, USA. 10Erasmus MC,
Rotterdam, The Netherlands. 11American Leprosy Missions, Greenville, USA.
12Chinese University of Hong Kong, Hong Kong, China.
Received: 22 January 2016 Accepted: 28 April 2016
References
1. Bakker MI, Hatta M, Kwenang A, Van Benthem BHB, Van Beers SM, Klatser
PR, et al. Prevention of leprosy using rifampicin as chemoprophylaxis. Am J
Trop Med Hyg. 2005;72(4):443–8.
2. Moet FJ, Pahan D, Oskam L, Richardus JH, COLEP Study Group. Effectiveness
of single dose rifampicin in preventing leprosy in close contacts of patients
with newly diagnosed leprosy: cluster randomised controlled trial. BMJ.
2008;336(7647):761–4.
3. Smith CM, Smith WC. Chemoprophylaxis is effective in the prevention of
leprosy in endemic countries: a systematic review and meta-analysis. MILEP2
Study Group. Mucosal Immunology of Leprosy. J Infect. 2000;41(2):137–42.
4. Richardus RA, Alam K, Pahan D, et al. The combined effect of
chemoprophylaxis with single dose rifampicin and immunoprophylaxis with
BCG to prevent leprosy in contacts of newly diagnosed leprosy cases: a cluster
randomized controlled trial (MALTALEP study). BMC Infect Dis. 2013;13:456.
5. WHO | Tuberculosis. http://www.who.int/mediacentre/factsheets/fs104/en/.
Accessed 17 June 2015.
6. Gagneux S, DeRiemer K, Van T, Kato-Maeda M, De Jong BC, Narayanan S,
et al. Variable host-pathogen compatibility in Mycobacterium tuberculosis.
Proc Natl Acad Sci U S A. 2006;103(8):2869–73.
7. David HL. Probability distribution of drug-resistant mutants in unselected
populations of Mycobacterium tuberculosis. Appl Microbiol. 1970;20(5):810–4.
8. Gagneux S, Long CD, Small PM, Van T, Schoolnik GK, Bohannan BJM. The
competitive cost of antibiotic resistance in Mycobacterium tuberculosis.
Science. 2006;312(5782):1944–6.
9. Comas I, Borrell S, Roetzer A, Rose G, Malla B, Kato-Maeda M, et al.
Whole-genome sequencing of rifampicin-resistant Mycobacterium
tuberculosis strains identifies compensatory mutations in RNA
polymerase genes. Nat Genet. 2012;44(1):106–10.
10. Mitchison DA. Drug resistance in Mycobacteria. Br Med Bull. 1984;40(1):84–90.
11. Colijn C, Cohen T, Ganesh A, Murray M. Spontaneous emergence of
multiple drug resistance in tuberculosis before and during therapy. PLoS
One. 2011;6(3), e18327.
12. Den Hertog AL, Menting S, Van Soolingen D, Anthony RM. Mycobacterium
tuberculosis Beijing genotype resistance to transient rifampin exposure.
Emerg Infect Dis. 2014;20(11):1932–3.
13. Chang KC, Leung CC, Grosset J, Yew WW. Treatment of tuberculosis and
optimal dosing schedules. Thorax. 2011;66(11):997–1007.
Mieras et al. Infectious Diseases of Poverty  (2016) 5:46 Page 4 of 5
14. Mitchison DA. How drug resistance emerges as a result of poor compliance
during short course chemotherapy for tuberculosis. Int J Tuberc Lung Dis
Off J Int Union Tuberc Lung Dis. 1998;2(1):10–5.
15. Jindani A, Aber VR, Edwards EA, Mitchison DA. The early bactericidal
activity of drugs in patients with pulmonary tuberculosis. Am Rev Respir
Dis. 1980;121(6):939–49.
16. Selkon JB, Devadatta S, Kulkarni KG, Mitchison DA, Narayana AS, Nair CN,
et al. The emergence of isoniazid- resistant cultures in patients with
pulmonary tuberculosis during treatment with isoniazid alone or isoniazid
plus PAS. Bull World Health Organ. 1964;31:273–94.
17. Mitchison DA, Jindani A, Davies GR, Sirgel F. Isoniazid activity is
terminated by bacterial persistence. J Infect Dis. 2007;195(12):1871–2.
author reply 1872–3.
18. Vernon A. Treatment of latent tuberculosis infection. Semin Respir Crit Care
Med. 2013;34(1):67–86.
19. Levy SB. Antibiotic resistance: consequences of inaction. Clin Infect Dis Off
Publ Infect Dis Soc Am. 2001;33 Suppl 3:S124–9.
20. 3d APR Union conference 8–11 July 2011, Hong Kong. WHO the STOP TB
department. http://www.antitb.org.hk/apr2011/8th%20july/Plenary%20
lecture%20I/pl1_Global%20epidemiology%20of%20tuberculosis,%20past,
%20present%20and%20future.pdf. Accessed June 2015.
21. Ayles H, Schaap A, Nota A, Sismanidis C, Tembwe R, De Haas P, et al.
Prevalence of tuberculosis, HIV and respiratory symptoms in two Zambian
communities: implications for tuberculosis control in the era of HIV. PLoS
One. 2009;4(5), e5602.
22. Corbett EL, Zezai A, Cheung YB, Bandason T, Dauya E, Munyati SS, et al.
Provider-initiated symptom screening for tuberculosis in Zimbabwe:
diagnostic value and the effect of HIV status. Bull World Health Organ.
2010;88(1):13–21.
23. Shapiro A, Golub JA. Systematic review of active case-finding strategies in
risk groups for tuberculosis (TB) and the relationship to the number needed
to screen; report to WHO. 2012. http://www.who.int/tb/Review3NNS_case_
active_TB_riskgroups.pdf. Accessed September 2015.
24. Systematic Screening for Active Tuberculosis: Principles and Recommendations.
Geneva: World Health Organization; 2013. http://www.ncbi.nlm.nih.gov/books/
NBK294083/. Accessed June 2015.
25. Hoog AH van’t, Langendam MW, Mitchell E, Cobelens FG, Sinclair D,
Leeflang MMG, et al. A systematic review of the sensitivity and specificity of
symptom and chest radiography screening for active pulmonary
tuberculosis in HIV negative persons and persons with unknown HIV status.
WHO. 2013. http://www.who.int/tb/Review2Accuracyofscreeningtests.
pdf?ua=1. Accessed September 2015.
26. Warren RM, Victor TC, Streicher EM, Richardson M, Beyers N, Van Pittius NC
G, et al. Patients with active tuberculosis often have different strains in the
same sputum specimen. Am J Respir Crit Care Med. 2004;169(5):610–4.
27. Cambau E, Chauffour-Nevejans A, Tejmar-Kolar L, et al. Detection of antibiotic
resistance in leprosy using GenoType LepraeDR, a novel ready-to-use
molecular test. PLoS Negl Trop Dis. 2012;6, e1739.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Mieras et al. Infectious Diseases of Poverty  (2016) 5:46 Page 5 of 5
